Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug 24:17:28-30.
doi: 10.1016/j.jdcr.2021.08.017. eCollection 2021 Nov.

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet

Affiliations
Case Reports

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet

Jeffrey A Bubley et al. JAAD Case Rep. .
No abstract available

Keywords: PPP, palmoplantar psoriasis; TCA, trichloroacetic acid; chemical peel; gentian violet; palmoplantar; psoriasis.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Left sole of the patient before her first treatment. Large, hyperpigmented lichenified plaque extending from the distal midplantar part of the foot to the proximal midplantar part of the foot with significant scale.
Fig 2
Fig 2
Four weeks after the first treatment with the 40% TCA peel and gentian violet application. The patient noted a significant improvement of the scale, itch, and redness of her soles. Residual postinflammatory hyperpigmentation was noted.
Fig 3
Fig 3
Four weeks after the second treatment with TCA 40% and gentian violet. The patient reports continued improvement of her itch, scaling, and redness. Lichenified plaques of the posterior parts of the soles, which were previously confluent, were starting to resolve. Residual postinflammatory hyperpigmentation is still observed.

References

    1. Kobayashi K., Kamekura R., Kato J. Cigarette smoke underlies the pathogenesis of palmoplantar pustulosis via an IL-17A-induced production of IL-36γ in tonsillar epithelial cells. J Invest Dermatol. 2021;141(6):1533–1541.e4. doi: 10.1016/j.jid.2020.09.028. - DOI - PubMed
    1. Czarnowicki T., Rosendorff B.P., Lebwohl M.G. Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasis. Cutis. 2020;106(1):E15–E17. doi: 10.12788/cutis.0042. - DOI - PubMed
    1. Bissonnette R., Pariser D.M., Wasel N.R. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99–105. doi: 10.1016/j.jaad.2016.02.1164. - DOI - PubMed
    1. Quiroz F.G., Fiore V.F., Levorse J. Liquid-liquid phase separation drives skin barrier formation. Science. 2020;367(6483):eaax9554. doi: 10.1126/science.aax9554. - DOI - PMC - PubMed
    1. Maley A.M., Arbiser J.L. Gentian violet: a 19th century drug re-emerges in the 21st century. Exp Dermatol. 2013;22(12):775–780. doi: 10.1111/exd.12257. - DOI - PMC - PubMed

Publication types

LinkOut - more resources